Top Markets
#1 EXOD EXOD +56.80%
#2 Arowana Arowana +8.49%
#3 Fake World Assets Fake World Assets +8.26%
#4 Perle Perle +3.98%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +3.72%
#6 Dual Dual +3.58%
#7 Casper Network Casper Network +3.58%
#8 Figure Heloc Figure Heloc +3.49%
#9 Movement Movement +3.23%
#10 Orochi Network Orochi Network +3.13%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
Evgen Pharma plc Evgen Pharma plc

Evgen Pharma plc

EVG
株式のランク #38016
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates... Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
株価
$0.00953895
最終同期: 2024-05-22
時価総額
$1.28M
変化（1日）
0.06%
変化（1年）
0.00%
国
GB
取引 Evgen Pharma plc (EVG)

カテゴリー

Healthcare
Evgen Pharma plc（EVG）の収益
Aug 2026 時点の収益 TTM: 0
Evgen Pharma plc の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Evgen Pharma plc の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE